Comment
doi: 10.1128/AAC.01295-12.
Reduced pupil diameter in volunteers on stable buprenorphine maintenance therapy with telaprevir: a drug-drug interaction involving p-glycoprotein at the blood-brain barrier?
- PMID: 23074230
- PMCID: PMC3486590
- DOI: 10.1128/AAC.01295-12
Item in Clipboard
Comment
Reduced pupil diameter in volunteers on stable buprenorphine maintenance therapy with telaprevir: a drug-drug interaction involving p-glycoprotein at the blood-brain barrier?
Antimicrob Agents Chemother.
2012 Nov.
No abstract available
Comment on
-
Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy.Antimicrob Agents Chemother. 2012 Jul;56(7):3641-7. doi: 10.1128/AAC.00077-12. Epub 2012 May 7. Antimicrob Agents Chemother. 2012. PMID: 22564847 Free PMC article. Clinical Trial.
Similar articles
-
Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy.Antimicrob Agents Chemother. 2012 Jul;56(7):3641-7. doi: 10.1128/AAC.00077-12. Epub 2012 May 7. Antimicrob Agents Chemother. 2012. PMID: 22564847 Free PMC article. Clinical Trial.
-
The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment.J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):480-4. doi: 10.1097/QAI.0b013e3182961d31. J Acquir Immune Defic Syndr. 2013. PMID: 23599011
-
Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.Am J Drug Alcohol Abuse. 2011 Jul;37(4):224-8. doi: 10.3109/00952990.2011.568081. Epub 2011 Mar 28. Am J Drug Alcohol Abuse. 2011. PMID: 21438849 Clinical Trial.
-
Pharmacologic treatments for opioid dependence: detoxification and maintenance options.Dialogues Clin Neurosci. 2007;9(4):455-70. doi: 10.31887/DCNS.2007.9.2/hkleber. Dialogues Clin Neurosci. 2007. PMID: 18286804 Free PMC article. Review.
-
Spotlight on buprenorphine/naloxone in the treatment of opioid dependence.CNS Drugs. 2009 Oct;23(10):899-902. doi: 10.2165/11203740-000000000-00000. CNS Drugs. 2009. PMID: 19739698 Review.
Cited by
-
Pupillary motility: bringing neuroscience to the psychiatry clinic of the future.Curr Neurol Neurosci Rep. 2013 Aug;13(8):365. doi: 10.1007/s11910-013-0365-0. Curr Neurol Neurosci Rep. 2013. PMID: 23780801 Free PMC article. Review.
References
-
- Alhaddad H, et al. Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice. Crit. Care Med., in press - PubMed
-
- Garg V, et al. 2011. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J. Clin. Pharmacol. doi:10.1177/0091270011419850 - DOI - PubMed
-
- Kobayashi K, et al. 1998. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab. Dispos. 26:818–821 - PubMed
-
- Mégarbane B, et al. 2006. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol. Appl. Pharmacol. 212:256–267 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
